공고 • Jun 01
Sawai Group Holdings Co., Ltd. to Report Q1, 2027 Results on Aug 10, 2026 Sawai Group Holdings Co., Ltd. announced that they will report Q1, 2027 results at 1:00 PM, Tokyo Standard Time on Aug 10, 2026 공고 • May 15
Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 25, 2026 Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 25, 2026. 공고 • Feb 20
Sawai Group Holdings Co., Ltd. to Report Fiscal Year 2026 Results on May 15, 2026 Sawai Group Holdings Co., Ltd. announced that they will report fiscal year 2026 results at 3:00 PM, Tokyo Standard Time on May 15, 2026 공고 • Nov 27
Sawai Group Holdings Co., Ltd. to Report Q3, 2026 Results on Feb 13, 2026 Sawai Group Holdings Co., Ltd. announced that they will report Q3, 2026 results at 1:00 PM, Tokyo Standard Time on Feb 13, 2026 공고 • Oct 21
Sawai Pharmaceutical Co., Ltd. Announces Settlement of Lawsuit Sawai Group Holdings Co., Ltd. announced that Sawai Pharmaceutical Co., Ltd. has reached a settlement dated October 20, 2025, with Asahi Kasei Pharma Corporation regarding a patent infringement lawsuit concerning TERIPARATIDE for Subcutaneous Injection 56.5ug. Sawai Pharmaceutical had been requested by Asahi Kasei Pharma to cease the manufacturing and sale of its generic teriparatide product and to pay damages for patent infringement, based on the process patent (Patent No. 6025881) related to Teribone 56.5 ug for subcutaneous injection. Sawai Pharmaceutical's claim was not upheld, and on September 26, 2024, The Osaka District Court issued an order preventing the manufacture and sale of the product using the patented method in question and requiring the payment of damages. An appeal was filed with the Intellectual Property High Court of Japan (hereinafter the "IP High Court") against this ruling; however, after carefully considering the overall terms of the settlement, Sawai Pharmaceutical determined that resolving the matter through settlement was a reasonable course of action and reached an agreement accordingly. Sawai Pharmaceutical paid Asahi Kasei Pharma JPY 4 billion yen as a settlement, and Asahi Kasei Pharma waived any other claims against Sawai Pharmaceutical. Details of the settlement will not be disclosed due to confidentiality obligations contained in the settlement terms. 공고 • Aug 19
Sawai Group Holdings Co., Ltd. to Report Q2, 2026 Results on Nov 14, 2025 Sawai Group Holdings Co., Ltd. announced that they will report Q2, 2026 results at 3:00 PM, Tokyo Standard Time on Nov 14, 2025 공고 • Jul 02
Sawai Group Holdings Co., Ltd. (TSE:4887) completed the acquisition of FrontAct Co., Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506). Sawai Group Holdings Co., Ltd. (TSE:4887) agreed to acquire FrontAct Co., Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) on March 28, 2025.
The expected completion of the transaction is June 30, 2025.
Sawai Group Holdings Co., Ltd. (TSE:4887) completed the acquisition of FrontAct Co., Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) on June 30, 2025. 공고 • Jun 02
Sawai Group Holdings Co., Ltd. to Report Q1, 2026 Results on Aug 12, 2025 Sawai Group Holdings Co., Ltd. announced that they will report Q1, 2026 results at 1:00 PM, Tokyo Standard Time on Aug 12, 2025 공고 • May 14
Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 25, 2025 Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 25, 2025. 공고 • Mar 01
Sawai Group Holdings Co., Ltd. to Report Fiscal Year 2025 Results on May 14, 2025 Sawai Group Holdings Co., Ltd. announced that they will report fiscal year 2025 results on May 14, 2025 공고 • Nov 30
Sawai Group Holdings Co., Ltd. to Report Q3, 2025 Results on Feb 14, 2025 Sawai Group Holdings Co., Ltd. announced that they will report Q3, 2025 results on Feb 14, 2025 공고 • Aug 28
Sawai Group Holdings Co., Ltd. to Report Q2, 2025 Results on Nov 11, 2024 Sawai Group Holdings Co., Ltd. announced that they will report Q2, 2025 results on Nov 11, 2024 공고 • Jun 25
Sawai Group Holdings Co., Ltd. (TSE:4887) announces an Equity Buyback for 6,900,000 shares, representing 15.75% for ¥33,000 million. Sawai Group Holdings Co., Ltd. (TSE:4887) announces a share repurchase program. Under the program, the company will repurchase up to 6,900,000 shares, representing 15.75% of its share capital, for ¥33,000 million. The purpose of the program is capital efficiency improvement and improve shareholder return. The program will expire on March 31, 2025. As of May 31, 2024, the company had 43,802,973 shares in issue (excluding treasury stock) and 366 shares in treasury. 공고 • Jun 06
Sawai Group Holdings Co., Ltd. to Report Q1, 2025 Results on Aug 09, 2024 Sawai Group Holdings Co., Ltd. announced that they will report Q1, 2025 results on Aug 09, 2024 공고 • May 15
Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 25, 2024 Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 25, 2024. 공고 • Apr 03
Bora Pharmaceuticals Co., LTD. (TWSE:6472) completed the acquisition of Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd. (TSE:4887). Bora Pharmaceuticals Co., LTD. (TWSE:6472) agreed to acquire Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd. (TSE:4887) for approximately $210 million on January 16, 2024.The closing of the transaction is subject to customary regulatory approvals, United States antitrust authorities and in accordance with other laws and regulations. As of January 17, 2024, Trading value of equity interest $160 million and $8 million upon the achievement of the conditions of Earnout, and the equivalent of $40 million value from Upsher-Smith separately through dividends or a repurchase of SAH shares held by Sawai Group. The expected closing date of the transaction is March 17, 2024. BDO Taiwan CPA Firm acted as accountant to Bora Pharmaceuticals. Stifel Financial Corp. (NYSE:SF) acted financial advisor to Sawai Group Holdings Co., Ltd. Andrew L. Bab, Rafael Kariyev, Peter F.G. Schuur, Henry Lebowitz, Paul D. Rubin, Melissa Runsten, Kim T. Le, M. Natasha Labovitz, Sidney P. Levinson of Debevoise & Plimpton LLP and Katten Muchin Rosenman LLP both acted as legal advisor to Sawai Group Holdings Co., Ltd.Bora Pharmaceuticals Co., LTD. (TWSE:6472) completed the acquisition of Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd. (TSE:4887) on April 1, 2024. 공고 • Mar 02
Sawai Group Holdings Co., Ltd. to Report Q4, 2024 Results on May 13, 2024 Sawai Group Holdings Co., Ltd. announced that they will report Q4, 2024 results on May 13, 2024 공고 • Nov 27
Sawai Group Holdings Co., Ltd. to Report Q3, 2024 Results on Feb 14, 2024 Sawai Group Holdings Co., Ltd. announced that they will report Q3, 2024 results on Feb 14, 2024 공고 • Aug 27
Sawai Group Holdings Co., Ltd. to Report Q2, 2024 Results on Nov 10, 2023 Sawai Group Holdings Co., Ltd. announced that they will report Q2, 2024 results on Nov 10, 2023 공고 • May 31
Sawai Group Holdings Co., Ltd. to Report Q1, 2024 Results on Aug 09, 2023 Sawai Group Holdings Co., Ltd. announced that they will report Q1, 2024 results on Aug 09, 2023 공고 • May 11
Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 27, 2023 Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 27, 2023. 공고 • Nov 30
Sawai Group Holdings Co., Ltd. to Report Q3, 2023 Results on Feb 13, 2023 Sawai Group Holdings Co., Ltd. announced that they will report Q3, 2023 results on Feb 13, 2023